Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

astrazeneca peru s.a. - droguerÍa - clorhidrato de metformina; dapagliflozina; - comprimido recubierto de liberacion prolongada - por tableta - - metformina y dapaglifozina

Unión Europea - español - EMA (European Medicines Agency)

astrazeneca ab - metformina clorhidrato, saxagliptin, dapaglifozina - diabetes mellitus, tipo 2 - drogas usadas en diabetes - qtrilmet está indicado en adultos mayores de 18 años con diabetes mellitus tipo 2:para mejorar el control glucémico cuando la metformina con o sin sulfonilureas (su) y saxagliptina o dapaglifozina no proporcionan un adecuado control de la glucemia. cuando ya están siendo tratados con metformina y saxagliptina y dapaglifozina.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

astrazeneca peru s.a. - clorhidrato de metformina; dapagliflozina; - tableta recubierta de liberacion prolongada - por tableta; clorhidrato de metformina 502.610000 mg; dapagliflozina 12.300000 mg; - metformina y dapaglifozina

Unión Europea - español - EMA (European Medicines Agency)

astrazeneca ab  - metformina clorhidrato, saxagliptin clorhidrato de - diabetes mellitus, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - komboglyze está indicado como complemento de la dieta y el ejercicio para mejorar el control glucémico en pacientes adultos de 18 años de edad y mayores con diabetes mellitus tipo 2 inadecuadamente controlan con su dosis máximo tolerada de metformina sola o los que ya tratados con la combinación de saxagliptina y metformina como tabletas separadas. komboglyze también está indicado en combinación con insulina (i. terapia de combinación triple) como complemento a la dieta y el ejercicio para mejorar el control glucémico en pacientes adultos mayores de 18 años con diabetes mellitus de tipo 2 cuando la insulina y metformina por sí solos no proporcionan un adecuado control de la glucemia.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

astrazeneca peru s.a. - droguerÍa - clorhidrato de metformina; dapagliflozina; - comprimido recubierto de liberacion prolongada - por tableta - - metformina y dapaglifozina

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , terapia de combinación triple) como complemento a la dieta y ejercicio en pacientes inadecuadamente controlados en su máxima dosis tolerada de metformina y una sulfonilurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, tipo 2 - drogas usadas en diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 y 5. 1 para datos disponibles sobre diferentes combinaciones).

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

astrazeneca peru s.a. - dapagliflozina; clorhidrato de metformina; - comprimido recubierto de liberacion prolongada - por comprimido - metformina y dapaglifozina

Unión Europea - español - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , terapia de combinación triple) como complemento a la dieta y ejercicio en pacientes inadecuadamente controlados en su máxima dosis tolerada de metformina y una sulfonilurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , terapia de combinación triple) como complemento a la dieta y ejercicio en pacientes inadecuadamente controlados en su máxima dosis tolerada de metformina y una sulfonilurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.